Agenda

Saturday October 19, 2024

• 8:00 AM – 8:05 AM

  Welcome

• 8:05 AM – 8:20 AM

  Debate: Best Targeted Therapy for First-Line Gastroesophageal Cancer: PD-1 Inhibitors or Claudin-18.2 (CLDN18.2)? - PD-1 INHIBITORS

  • Presenter
    • Ryan MoyMD, PhD
• 8:20 AM – 8:35 AM

  Debate: Best Targeted Therapy for First-Line Gastroesophageal Cancer: PD-1 Inhibitors or Claudin-18.2 (CLDN18.2)? - CLDN18.2

  • Presenter
    • Michael GibsonMD, PhD
• 8:35 AM – 8:45 AM

  Debate: Best Targeted Therapy for First-Line Gastroesophageal Cancer: PD-1 Inhibitors or Claudin-18.2 (CLDN18.2)? - DISCUSSION

  • Panelist
    • Michael GibsonMD, PhD
    • Ryan MoyMD, PhD
• 8:45 AM – 9:00 AM

  Debate: MSI Tumors: Does Anatomic Location Affect the Management? - YES

  • Presenter
    • Lakshmi RajdevMD, MS
• 9:00 AM – 9:15 AM

  Debate: MSI Tumors: Does Anatomic Location Affect the Management? - NO

  • Presenter
    • Nataliya UbohaMD, PhD
• 9:15 AM – 9:25 AM

  Debate : MSI Tumors: Does Anatomic Location Affect the Management? Yes vs No - DISCUSSION

  • Panelist
    • Lakshmi RajdevMD, MS
    • Nataliya UbohaMD, PhD
• 9:25 AM – 9:35 AM

  Break

• 9:35 AM – 10:35 AM

  Non-CME Innovation Theater - Sponsored by IPSEN

• 10:35 AM – 11:15 AM

  Optimizing Outcomes in Advanced/Metastatic Gastric and Gastroesophageal Junction Cancer: A Focus on Novel and Emerging HER2-Negative Targeted Treatment Strategies

  • Presenter
    • Thomas CartwrightMD